These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension. Ali J; Wu J; Hassan M; Tsai JH; Touba N; McCarrier K; Ballard M; Chatterjee A Pulm Ther; 2024 Sep; 10(3):315-330. PubMed ID: 39012432 [TBL] [Abstract][Full Text] [Related]
23. The role of amikacin in the treatment of nontuberculous mycobacterial disease. Raaijmakers J; Schildkraut JA; Hoefsloot W; van Ingen J Expert Opin Pharmacother; 2021 Oct; 22(15):1961-1974. PubMed ID: 34292097 [No Abstract] [Full Text] [Related]
25. Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. Mingora CM; Garcia BA; Mange KC; Yuen DW; Ciesielska M; van Ingen J; Flume PA; Dorman SE BMC Infect Dis; 2022 Mar; 22(1):246. PubMed ID: 35279081 [TBL] [Abstract][Full Text] [Related]
26. Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend. Griffith DE; Aksamit TR Chest; 2021 Apr; 159(4):1372-1381. PubMed ID: 33080299 [TBL] [Abstract][Full Text] [Related]
27. Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages. Zhang J; Leifer F; Rose S; Chun DY; Thaisz J; Herr T; Nashed M; Joseph J; Perkins WR; DiPetrillo K Front Microbiol; 2018; 9():915. PubMed ID: 29867826 [TBL] [Abstract][Full Text] [Related]
28. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. Yagi K; Ishii M; Namkoong H; Asami T; Iketani O; Asakura T; Suzuki S; Sugiura H; Yamada Y; Nishimura T; Fujiwara H; Funatsu Y; Uwamino Y; Kamo T; Tasaka S; Betsuyaku T; Hasegawa N BMC Infect Dis; 2017 Aug; 17(1):558. PubMed ID: 28793869 [TBL] [Abstract][Full Text] [Related]
29. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. Davis KK; Kao PN; Jacobs SS; Ruoss SJ BMC Pulm Med; 2007 Feb; 7():2. PubMed ID: 17319962 [TBL] [Abstract][Full Text] [Related]
30. Treatment of severe Zweijpfenning SMH; Kops SEP; Boeree MJ; Kuipers S; van Ingen J; Hoefsloot W; Magis-Escurra C ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34820449 [No Abstract] [Full Text] [Related]
31. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Olivier KN; Shaw PA; Glaser TS; Bhattacharyya D; Fleshner M; Brewer CC; Zalewski CK; Folio LR; Siegelman JR; Shallom S; Park IK; Sampaio EP; Zelazny AM; Holland SM; Prevots DR Ann Am Thorac Soc; 2014 Jan; 11(1):30-5. PubMed ID: 24460437 [TBL] [Abstract][Full Text] [Related]
32. Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Kim BG; Kim H; Kwon OJ; Huh HJ; Lee NY; Baek SY; Sohn I; Jhun BW J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32937940 [TBL] [Abstract][Full Text] [Related]
33. Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages. Kesavalu L; Goldstein JA; Debs RJ; Düzgünes N; Gangadharam PR Tubercle; 1990 Sep; 71(3):215-7. PubMed ID: 2238129 [TBL] [Abstract][Full Text] [Related]
34. Laryngitis after inhalation of liposomal amikacin. Morita A; Namkoong H; Hosoya M; Hasegawa N Clin Case Rep; 2022 Feb; 10(2):e05350. PubMed ID: 35369384 [TBL] [Abstract][Full Text] [Related]
35. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides. Bermudez LE; Yau-Young AO; Lin JP; Cogger J; Young LS J Infect Dis; 1990 Jun; 161(6):1262-8. PubMed ID: 2345306 [TBL] [Abstract][Full Text] [Related]
38. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Olivier KN; Griffith DE; Eagle G; McGinnis JP; Micioni L; Liu K; Daley CL; Winthrop KL; Ruoss S; Addrizzo-Harris DJ; Flume PA; Dorgan D; Salathe M; Brown-Elliott BA; Gupta R; Wallace RJ Am J Respir Crit Care Med; 2017 Mar; 195(6):814-823. PubMed ID: 27748623 [TBL] [Abstract][Full Text] [Related]
39. Lack of activities of amikacin and sulphamethoxazole against Mycobacterium avium-intracellulare. Yew WW; Tam CM; Chan CY; Li MS; Cheng AF Int J Clin Pharmacol Res; 1993; 13(2):65-8. PubMed ID: 8354590 [TBL] [Abstract][Full Text] [Related]
40. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]